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PDGFsignaling regulates thedevelopment ofmesen-
chymal cell types in the embryo and in the adult, but
the role of receptor activation in tissue homeostasis
has not been investigated.We have generated condi-
tional knockin mice with mutations in PDGFRa that
drive increased kinase activity under the control of
the endogenous PDGFRa promoter. In embryos,
increased PDGFRa signaling leads to hyperplasia of
stromal fibroblasts, which disturbs normal smooth
muscle tissue in radially patterned organs. In adult
mice, elevated PDGFRa signaling also increases
connective tissue growth, leading to a progressive
fibrosis phenotype in multiple organs. Increased
PDGFRa signaling in an Ink4a/Arf-deficient genetic
background leads to acceleratedfibrosis, suggesting
a new role for tumor suppressors in attenuating
fibrotic diseases. These results highlight the role of
PDGFRa in normal connective tissue development
and homeostasis and demonstrate a pivotal role for
PDGFRa signaling in systemic fibrosis diseases.
INTRODUCTION
Platelet-derived growth factors (PDGF) exert their biological
effects through thebindingandactivationof two receptor tyrosine
kinases, PDGFRa and b. Ligand binding to PDGFRa/b on the cell
surface induces receptor oligomerization and tyrosine phosphor-
ylation, activating a number of downstream signal transduction
pathways, including Ras/MAP kinases, PI3 kinase/AKT, and
PLC/PKC pathways. The cellular responses to PDGF signaling
include proliferation, survival, migration, and control of differenti-
ation, and PDGFRa signaling serves critical functions during
embryo development (Andrae et al., 2008; Hoch and Soriano,
2003; Soriano, 1997); however, the consequences of increased
signaling in development and in the adult are unknown.
PDGFRa-activating mutations might be expected to disrupt
some or all of the tissues in which developmental functions
have been previously identified. However, most mesenchymal
progenitors in the early embryo express PDGFRa; therefore,
increased signaling could have more broad effects and has the
potential to suggest new developmental roles of PDGFRa.DevelopPDGF receptors are tightly regulated by an autoinhibitory allo-
steric conformation, resulting in very low basal activity in the
absence of ligand. Constitutively active versions of PDGF recep-
tors carrying point mutations that relieve autoinhibition were first
generated and characterized in tissue culture (Irusta and DiMaio,
1998). More recently, a small percentage (5%) of gastrointes-
tinal stromal tumors (GIST) have been found to carry small dele-
tions, insertions, and point mutations in PDGFRa that result in
constitutive activity (Heinrich et al., 2003; Hirota et al., 2003). In
GISTs, there is a strong mutational bias toward PDGFRa muta-
tions in the activation loop of the kinase domain (82%–93%),
with mutations in the juxtamembrane domain being the second
most frequent site of mutation (7%–13%) (Corless et al., 2005).
Two weakly activating PDGFRamutations have been associated
with familial casesofGISTorGISTvariants (Chompret et al., 2004;
de Raedt et al., 2006); however, developmental defects have yet
to be linked to strongly activating mutations in this receptor.
Aberrant PDGFR signaling has also been implicated in diverse
fibrotic conditions (Andrae et al., 2008) in which fibroblasts
proliferate and deposit excessive connective tissue matrix,
leading to progressive scarring and organ dysfunction. Systemic
sclerosis, or scleroderma, is an autoimmune disease afflicting
an estimated 300,000 people in the United States. The disease
is characterized by chronic autoimmune reactions, microvas-
cular restriction, and widespread fibrosis of the skin and other
organs, including the gastrointestinal system, skeletal muscle,
heart, kidney, and lungs, frequently resulting in organ failure
and death (Samter, 1988). Although the initiating events for
this disease are unknown, and no single model explains all
scleroderma-related pathology, it was recently shown that
systemic sclerosis patients circulate autoactivating antibodies
for PDGFRa/b in their serum, suggesting that systemic autoan-
tibody stimulation of PDGFR-expressing fibroblasts could be
involved in the disease (Baroni et al., 2006). Experimental activa-
tion of TGFb signaling has been shown to recreate fibrotic
pathology in the skin (Sonnylal et al., 2007), and this may act
in part by increasing the level of PDGF signaling (Bonner,
2004; Yamakage et al., 1992). Nevertheless, there is currently
no animal model representing a PDGF component of the
disease (Christner and Jimenez, 2004).
To investigate the in vivo consequences of increased PDGFRa
signaling and to gain new understanding of the developmental
biology of this receptor and the consequences for disease in
adulthood, we created activatable alleles with higher intrinsic
kinase activity at the PDGFRa locus. Two separate mouse linesmental Cell 16, 303–313, February 17, 2009 ª2009 Elsevier Inc. 303
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SignalingbyPDGFRaMutantcDNAKnockins
(A) Schematic of the PDGFRa cDNA knockin
vector and the wild-type PDGFRa genomic locus.
Open triangles indicate loxP sites. Vertical rectan-
gles on the lower, genomic schematic indicate the
approximate locations of exons 1–6, and hori-
zontal rectangles underneath indicate the location
of probes used for the Southern blot. Note: the
50 probe and the Dstop Southern blots are shown
in Figure S1. SA, splice acceptor; R1, EcoR1;
N, Nhe1.
(B) Schematic of the two different PDGFRa
mutants generated in this study. Shaded circles
indicate amino acid changes in the juxtamem-
brane domain (aJ) or kinase domain (aK).
(C) Southern blot analysis of wild-type (+/+) and
lox-stop-lox aK-targeted (+/(S)K) ES cell DNA
digested with NheI. When probed with a
30 external probe, the appearance of a novel frag-
ment at 9kb indicates correct targeting of the
locus. Fragments of 20kb and 12kb represent
the wild-type locus. Southern blot analysis of
aJ clones was identical (not shown).
(D)WesternblotanalysisofPDGFRaproteinexpres-
sion and phosphorylation in PDGFRa+/+ (Wt),
PDGFRa+/J (aJ), and PDGFRa+/K (aK) embryos.
Protein lysates fromE13.5 embryos were subjected
to immunopreciptitation (‘‘IP’’) with PDGFRa antibody and were blotted for phosphotyrosine. Separately, equal amounts of total protein were blotted for PDGFRa.
(E–G) Primary mouse embryonic fibroblasts (MEFs) derived from PDGFRa+/+ (Wt), PDGFRa+/J (aJ), PDGFRa+/K (aK), or PDGFRa/K (/aK) embryos.
Cells were serum starved, then harvested directly () or stimulated with 10 ng/ml PDGF-AA (+). Protein lysates for PDGFRa analyses (E and F)
were treated the same as in (D), or (G) were instead blotted for phosphorylated signaling proteins. The expression of total signaling proteins
was the same in all samples, as determined by western blot (not shown).were generated for conditional expression of mutant PDGFRa
witheither juxtamembraneor kinasedomainmutations thatmimic
somaticmutations identified in humanGIST. The resulting pheno-
types were similar in type but differed in severity, thus providing
novel insight into the mutation bias seen in human GIST. The
developmental phenotypes resulting from either mutation
demonstrate an important role for PDGFRa in the balanced
expansion of mesenchymal cells during connective tissue devel-
opment. In adult animals, increased PDGFRa activation also
leads toconnective tissuehyperplasia and toprogressive,chronic
fibrosis in many organs. Finally, we find that loss of the Ink4a/Arf
tumor suppressor synergizes with aberrant PDGFRa signaling in
both tumorigenesis and the development of fibrotic disease.
RESULTS
Derivation of Knockin Mice
Previously, we described a generic knockin vector that drives
expression of a PDGFRa cDNA from the endogenous promoter
while simultaneously disrupting expression of the endogenous
PDGFRa gene (Klinghoffer et al., 2001). To explore the conse-
quences of mutant PDGFRa signaling, we modified this vector
by insertinga lox-stop-loxcassette so that transcription isblocked
until Cre recombination removes the stop cassette (Figure 1A). In
the absence of Cre recombination, knockin mice are heterozy-
gous for PDGFRa and are phenotypically normal (Soriano,
1997).We generated two lines of knockinmice harboring different
activating mutations that have been repeatedly isolated from
human tumors (Figure 1B). The first mutation (D842V), designated304 Developmental Cell 16, 303–313, February 17, 2009 ª2009 ElseaK, is located in the kinase domain and is thought to interfere with
the inactive conformation of the ATP-binding pocket, which leads
to constitutive activity. It is the single most common PDGFRa
mutation found in humanGISTs (Corless et al., 2005). The second
mutation (V561D), designated aJ, is the most common PDGFRa
juxtamembrane domain mutation found in GISTs. This mutation
is thought to lead to constitutive activity by disrupting inhibitory
contacts between the juxtamembrane and kinase domains that
are important for full autoinhibition (Hubbard, 2004). Correctly tar-
geted ES cell clones were identified by Southern blot analysis
(Figure 1C; see FigureS1available online) andwere used to derive
germline chimeras for the aK and aJ strains.
PDGFRa+/(S)K and PDGFRa+/(S)J heterozygous mice that
carried the inactivating lox-stop-lox cassette, designated (S),
were then crossed to Cre-expressing strains to obtain embryos
or mice with activated alleles. We initially tested the activated
alleles by crossing with the Meox2-Cre line, which drives recom-
bination in theepiblastand thereforeall cell lineagesof theembryo
proper (Tallquist andSoriano,2000).WesternblotsofPDGFRa+/+,
PDGFRa+/K, and PDGFRa+/J embryo lysates showed similar
expression levels of the receptor in all lines (Figure 1D). Immuno-
precipitation of PDGFRa followed by phosphotyrosine Western
blot indicated that mutant receptors were hyperphosphorylated,
reflecting their increased activation (Figure 1D).
Constitutive and Inducible PDGFRa Signaling
in Mutant Fibroblasts
PDGFRa-activating mutations like D842V and V561D allow for
high basal kinase activity without the addition of ligand (Heinrichvier Inc.
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can be further stimulated by ligand. To determine both basal
activity and examine the potential for superactivation in the pres-
ence of ligand, we cultured fibroblasts frommutant embryos and
examined PDGFRa phosphorylation. After 48 hr of serum starva-
tion, PDGFRa+/K and PDGFRa+/J fibroblasts retained elevated
basal phosphorylation of PDGFRa compared to wild-type cells
(Figure 1E), consistent with earlier work. Additionally, PDGFRa
from mutant cells became hyperphosphorylated after a pulse of
PDGF-AA (Figure 1E). This result indicates that PDGFRa+/K and
PDGFRa+/J cells remain responsive to their cognate ligands,
with stronger activation of the aK mutant receptor compared to
aJ (Figure S2). To test the contribution of the wild-type receptor
in this response, we derived PDGFRa/K fibroblasts expressing
onlyaK receptors. In these cells, a pulse of PDGF-AA still induced
elevated tyrosine phosphorylation of aK receptors (Figure 1F). It
was not possible to generate PDGFRaK/K or PDGFRaJ/J mutant
cell lines because PDGFRa+/K and PDGFRa+/J pups suffer
neonatal and juvenile lethality (see below), precluding further
crosses. Because mutant PDGFRa molecules can respond to
exogenous ligand, we conclude that they localize to the plasma
membrane and retain dimerization capabilities. This suggests
that developmental responses relying on a directional source of
ligand, such as chemotaxis by migrating fibroblasts, may still
function in the presence of mutant receptors.
We also measured the phosphorylation state of downstream
signaling molecules to see if increased signaling altered specific
pathways. There was little difference in the phosphorylation
status of Erk1/2 on Thr202/Tyr204 between mutant and wild-
type fibroblasts, with all cell lines displaying low basal phosphor-
ylation and prominent stimulation by PDGF-AA after 10 min.
Similar resultswereseen forAktphosphorylationonSer473under
basal conditions or in response to ligand. In contrast, PLCg1 was
constitutively phosphorylated on Tyr783 in mutant fibroblasts,
and thismodification appeared to be stronger in PDGFRa+/K cells
compared to PDGFRa+/J cells (Figure 1G; Figure S2). Based on
these observations, we predict that some biological processes
could remain unperturbed by activating Pdgra mutations as
long as differential PLCg1 activation is not critical.
PDGFRa+/K Embryos Exhibit Defects in Lung
Development, Edema, and Aberrant Skeletal Growth
We examined embryonic and neonatal viability in PDGFRa+/K
and PDGFRa+/J mice because human congenital defects have
not yet been linked to strongly activating mutations in PDGFRa.
Genotyping of offspring from crosses between PDGFRa+/(S)K (or
PDGFRa+/(S)J) and Meox2-Cre parents at postnatal days 7–14
indicated no PDGFRa+/K survivors (0/132 offspring) and a lower
than predicted frequency of PDGFRa+/J survivors (44/220
offspring=20%). However, PDGFRa+/K and PDGFRa+/J embryos
were recovered at the expected frequency until the time of birth
(Table S1). PDGF-A signaling through PDGFRa has previously
been shown to regulate the spreading and proliferation of
smooth muscle progenitors during postnatal alveolar develop-
ment (Bostro¨m et al., 1996). Histological analysis of lungs at
embryonic day (E18.5) showed a failure of terminal sackmorpho-
genesis, indicating that respiratory failure was a likely cause of
rapid death in PDGFRa+/K neonates. Instead of accomplishing
the final stage of embryonic lung development, PDGFRa+/KDevelopmembryos only reached the canalicular stage, and they exhibited
a 1.6-fold increase in mesenchymal cell density and wide-
spread PDGFRa expression when compared to PDGFRa+/J
and wild-type lungs (Figures 2A and 2B; Figure S3). The
PDGFRa+/K lung phenotype is similar to that reported for trans-
genic overexpression of PDGF-A under the surfactant protein
C promoter (Li and Hoyle, 2001), except that PDGFRa+/K lungs
were not larger than controls (data not shown). Loss of PDGFRa
signaling is known to affect somite-derived structures, resulting
in smaller embryos with subepidermal edema, as well as aber-
rant growth or fusion of rib and vertebral elements (Soriano,
1997). PDGFRa+/J embryos appeared normal in all of these
aspects, but PDGFRa+/K embryos were notably larger from
E12.5 to E16.5 and had uncondensed mesenchyme and edema
of the torso (Figures 2C and 2D). During the final days of embryo-
genesis the edema was normalized, with the development of
enlarged lymphatic structures (data not shown). Preparations
of wild-type and PDGFRa+/K skeletons at E18.5 revealed a
wide, unsegmented sternum (Figures 2E and 2F) that was likely
the result of incomplete contact between ribs and unfused
sternal bands at E16.5 (Chen, 1953) (Figures 2G and 2H). We
conclude that the increased severity of the PDGFRa+/K pheno-
type relative to that seen in PDGFRa+/J mutants may reflect
a threshold of PDGF signaling that is only achieved by the
more potent kinase domain mutation.
Increased PDGFRa Signaling Disrupts the Balanced
Development of Connective Tissue and Smooth Muscle
Although PDGFRa+/J mutants did not present a lung phenotype
and most survived until weaning, they all developed bilateral
hydronephrosis and distention of the proximal ureter (Figures
3A–3C). Enlargement of the renal pelvis was apparent in
PDGFRa+/J and PDGFRa+/K embryos as early as E16.5
(Figure 3C and data not shown). Urine transport from the kidney
to the bladder requires smooth muscle contraction in the ureter;
smoothmuscle defects can result in functional obstruction of the
ureter, which has been found to account for hydronephrosis in
other mouse models (Mendelsohn, 2006). A normal ureter is
composed of a specialized urothelium surrounded by smooth
muscle and two rings of stromal cells that generate connective
tissue (Figures 3D and 3G). In PDGFRa+/K and PDGFRa+/J
mutants, normal patterning was apparent when visualized by
staining with antibody for smooth muscle actin (aSMA).
However, stromal cells were hyperplastic, and smooth muscle
cells were poorly condensed (Figures 3E and 3F).We next exam-
ined PDGFRa/ embryos to see if this receptor might be
required in ureter development. PDGFRa/ ureters developed
smooth muscle and connective tissue populations, but they
were slightly smaller than wild-type controls (Figure S4),
suggesting partial compensation by other signals in normal
development. Smooth muscle differentiation commenced at
the expected time (E15.5) in PDGFRa+/J and PDGFRa+/K ureters,
as determined by aSMA expression, and serial sections of
mutant urogenital tracts at E15.5 or E18.5 did not reveal obstruc-
tions of the lumen (data not shown). Instead, stromal hyperplasia
appeared to disrupt the formation of a tight smoothmuscle layer,
leading to a nonfunctional ureter. In surviving PDGFRa+/J mice,
the excessive stroma eventually differentiated as a thick sheath
of collagenous connective tissue (Figures 3G and 3H).ental Cell 16, 303–313, February 17, 2009 ª2009 Elsevier Inc. 305
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(A and B) Hematoxylin and eosin staining of lung sections from E18.5 wild-type
(Wt) andPDGFRa+/K (aK)embryos. Inset: insituhybridization forPDGFRamRNA
(blue stain)with individual labeled cells inwild-type, orwithmasses of cells inaK.
(C and D) Whole embryos staged at E13.5. PDGFRa+/K embryos are enlarged
with edema and pools of blood.
(E and F) Skeletal preparations from E18.5 embryos. PDGFRa+/K skeletons
exhibit a shortened and thickened sternum lacking the normal bands of
residual cartilage (blue sternum components in [E]).306 Developmental Cell 16, 303–313, February 17, 2009 ª2009 ElseConnective tissue hyperplasia thus represents a novel develop-
mental mechanism for functional obstruction of the urinary tract.
We also noticed selective hyperplasia of stromal cells
throughout the digestive system, but most strikingly in the
esophagus and stomach (Figures 3I–3K and data not shown).
Radial patterning of the digestive system and urinary tract
involves conserved epithelial-mesenchymal signaling (Mendel-
sohn, 2006), but a role for PDGF in this process has not been
previously identified. We used Tbx18 as a specific marker to
identify the uretral mesenchyme (Figure 4A) (Airik et al., 2006)
and compared the expression of PDGF genes. PDGFA ligand
was expressed in the epithelium of developing ureters and gut
at E12.5, and PDGFC ligand was expressed in both the epithe-
lium and in a subpopulation of mesenchyme (Figures 4B and
4C). PDGFRa, the principal receptor for these ligands, was
broadly expressed in mesenchyme, including renal mesen-
chyme (Figure 4D). This pattern of PDGF ligand and receptor
expression persisted in wild-type ureters from E13.5 to E15.5
(Figures 3E–3G and data not shown), and a similar pattern was
seen in the E12.5 and older digestive system (Figures 4H–4J
and data not shown). Primary fibroblasts from PDGFRa+/J and
PDGFRa+/K embryos have increased growth potential when
cultured in vitro (Figure S3), and we therefore expected to find
a proliferation difference underlying the hyperplasic phenotypes.
Proliferation was not significantly increased at E13.5 in the
PDGFRa+/K ureter compared to the wild-type (Figures 4K–4M),
but in the esophagus the proliferation differencewas significantly
increased (Figures 4O–4Q). Even at E13.5 there weremanymore
mesenchymal cells per section of PDGFRa+/K ureter than in wild-
type sections (Figure 4N), suggesting that, in addition to prolifer-
ation, enhanced migration could endow the developing ureter
with a larger initial complement of uretral mesenchyme. Consis-
tent with the potential involvement of such a mechanism,
PDGFRa+/K cells showed increased migration toward PDGF-AA
compared to wild-type fibroblasts (Figure 4S). Therefore, aK
receptors with high basal phosphorylation are not blinded to
a directional source of ligand, and increased chemotaxis could
contribute to the hyperplastic phenotypes.
Widespread Fibrosis of Skin and Internal Organs
after Mosaic PDGFRa Activation in Adult Mice
Based on the connective tissue phenotypes we observed in the
embryo, and to explore the potential role of PDGF signaling in
adult fibrotic conditions, we induced mosaic activation of aJ
and aK alleles by using ROSA26-CreER mice that ubiquitously
express a tamoxifen (Tam)-inducible Cre enzyme (Badea et al.,
2003). We first generated cohorts by crossing PDGFRa+/K or
PDGFRa+/J mice with homozygous ROSA26CreER/CreER mice to
obtain mutant and wild-type animals, each with one copy of
ROSA26-CreER. We regulated the timing of activation by treat-
ing the animals with a single pulse of Tam (see Experimental
Procedures), and we achieved recombination efficiencies
ranging between 10% and 30% (average of 24% ± 7.2%), as
measured by real-time PCR at 5 days postinjection. To visualize
(GandH)Skeletal preparations fromE16.5embryos.All sevenpairsofwild-type
ribs make contact with the fused sternum bands, but several PDGFRa+/K ribs
(numbered) do not contact or have poor contact with the unfused sternum
bands. Atypical ossification correlates with poor rib-sternum contact.vier Inc.
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Gut and Ureter Mesenchyme in PDGFRa+/J
and PDGFRa+/K Embryos
(A) Whole kidneys, ureters, and bladder isolated
from a PDGFRa+/J survivor at postnatal day 28
(P28) with hydronephrosis.
(B and C) Sagittal kidney sections from E17.5 wild-
type (Wt) and PDGFRa+/J (aJ) embryos stained
with hematoxylin and eosin; hydronephrosis is
already apparent in PDGFRa+/J (asterisk).
(D–F) Transverse sections of distal ureters from
E18.5 wild-type (Wt), PDGFRa+/J (aJ), or
PDGFRa+/K (aK) embryos, with immunohisto-
chemistry (IHC) for a-smooth muscle actin
(brown). Smooth muscle appears as a single ring
with flanking rings of blue stromal cells. Stromal
components are hyperplastic inmutants (asterisks
in [E] and [F]).
(G and H) Ureters from P28 wild-type and
PDGFRa+/J pups stained with Masson’s tri-
chrome. Differentiated stromal components
(asterisks) produce collagen (blue stain); however,
inmutants, the outer collagen ring extends beyond
the microscope field. Fragmented urothelium in
(H) is an artifact of tissue processing.
(I–K) Transverse sections of esophagus from
E18.5 wild-type, PDGFRa+/J, and PDGFRa+/K
embryos with IHC for a-smooth muscle actin
(brown). Asterisks indicate hyperplastic stroma.this effect in situ, we injected Tam into ROSA26-CreERmice that
were also heterozygous for the ROSA26R-lacZ allele (Soriano,
1999). Frozen sections from these ROSA26CreER/RlacZ mice
showed mosaic b-galactosidase expression in nearly all tissues
(e.g., gut shown in Figure 5B).
Cohorts of Tam-treatedmice expressing wild-type, aJ, and aK
alleles were allowed to age for up to 76 weeks. Initial evaluation
of the mice did not reveal any change in morphology or health
status, and all animals grew to the normal size and weight. Start-
ing at 6 months after Tam treatment, PDGFRa+/K mice began to
develop symptoms of intestinal disease and eventually died or
had to be sacrificed (Figure 5C). All PDGFRa+/Kmice that under-
went necropsy (n=17) presented partial or complete fibrosis of
the small intestine and cecum, and histological examination
showed increased submucosal connective tissue with a propor-
tional increase in fibroblast-like cells and collagenous matrix
(Figures 5D–5I). Additionally, in 9/17 PDGFRa+/Kmutants, a vari-
able number of firm, white polyps ranging in size from 1 mm to
10 mm were associated with a fibrotic GI tract (Figure 5J). Of
the PDGFRa+/J mutants that underwent necropsy, 4/9 exhibited
intestinal fibrosis, and 1 had polyps (data not shown). GISTs are
thought to arise from interstitial cells of Cajal (ICCs), which are
pacemaker cells that associate with smoothmuscle and express
CD117/Kit. Constitutive activation of the Kit receptor tyrosine
kinase leads to ICC hyperplasia and serves as a mouse model
for GIST (Rubin et al., 2005; Sommer et al., 2003). None of our
mice developed ICC hyperplasia, and fibrotic intestine and
polyps did not express increased Kit or aSMA, but did increase
expression of PDGFRa (Figures 5K–5N). This demonstrates
a clear difference between the responses of cells that are sensi-Developtive to Kit or PDGFRa mutation, even though both RTKs have
been implicated in the pathogenesis of GISTs.
In addition to gastrointestinal fibrosis, allPDGFRa+/K and some
PDGFRa+/Jmutantsdeveloped tight skin that adheredstrongly to
underlying muscle. Histological analysis revealed that this
phenotype corresponded to structural changes in all subepi-
dermal connective tissue layers, with an expanded network of
dense collagen fibers and a proportional increase in the number
of fibroblasts (asterisk in Figures 6B and 6C). Connective tissue
fibrosis was also noted in heart muscle (arrows in Figure 6E),
around bronchioles (asterisk in Figure 6G), in skeletal muscle
(asterisk in Figure 6I), and in the kidney glomeruli and renal inter-
stitium, whereas vascular smooth muscle was unperturbed
(Figure S5). As in the digestive system, amilder and slower devel-
oping fibrosis phenotype was noted in PDGFRa+/J mutants
(quantified for various organs in Figure 6K). Expression of
PDGFRa was present in cells residing within regions of fibrosis,
and foci of higher expression could also be found, presumably
representing active lesions (Figure 6J). Consistent with the
in vitro analysis (Figure 1G), fibrotic tissue displayed elevated
PLCg1 phosphorylation (Figure 6L), suggesting a role for
PLCg1/PKC signaling in the observed fibrotic responses.
Loss of Ink4a/Arf Enhances Tumor Initiation
and Fibrosis Driven by PDGFRa
AberrantPDGFsignaling hasbeenassociatedwithseveral human
tumors, including sarcomas (Ostman and Heldin, 2007), and we
therefore expected some incidence of neoplasia in our mice.
However, spontaneous tumors were rare and late to appear in
Tam-induced cohorts on awild-typeB6/129 background. Amongmental Cell 16, 303–313, February 17, 2009 ª2009 Elsevier Inc. 307
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Early Stages of Radially Patterned Organo-
genesis
(A–G) In situ hybridization for specific expressed
genes in wild-type ureters at (A–D) E12.5 and
(E–G) E14.5. (A) Tbx18 probe identifies uretral
mesenchyme at E12.5. (B and E) PDGFA is
restricted to ureteric epithelium. (C and F) PDGFC
is found in both epithelium and a concentric ring
of uretral mesenchyme. (D and G) PDGFRa is
broadlyexpressed inperiuretralmesenchymecells.
(H–J) Expression of PDGF ligand and receptor
probes in E12.5 esophagus, revealing a similar
pattern to that seen in ureter.
(K and L) Representative transverse sections of
wild-type and PDGFRa+/K ureter at E13.5; BrdU+
cells are labeled brown, and negative cells are
labeled blue. White, dashed lines show the epithe-
lial-mesenchymal border.
(M and N) Quantification of proliferating cells (M)
and cell numbers per section (N) at E13.5 in the
analyzed uretral mesenchyme (mean ± standard
deviation of >10 ureter sections per genotype).
(O and P) Representative transverse sections of
wild-type and PDGFRa+/K esophagus at E13.5;
BrdU+ cells are labeled brown, and negative cells
are labeled blue. White, dashed lines show the
epithelial-mesenchymal border.
(Q and R) Quantification of proliferating cells (Q)
and cell numbers per section (R) at E13.5 in the
analyzed esophageal mesenchyme (mean ± stan-
dard deviation of four esophagus sections per
genotype).
(S) Migration of MEFs in a modified Boyden
chamber assay toward 10 ng/ml PDGF-AA. The
number of migrated cells (mean number of cells
per field ± standard deviation) was counted in
13 fields of 203 magnification (total cells
counted=283Wt, 425aK).Data are representative
of two independent assays performed in triplicate.29 PDGFRa+/K mice, 5 developed sarcomas between 44 and
76 weeks of age (mean 56 weeks). These sarcomas appeared to
arise from the dermis or muscle connective tissue and presented
numerous mitotic figures, pleiomorphic nuclei, little collagen
content, and infiltration of surrounding adipose and muscle.
PDGFRa was robustly expressed in these sarcomas (Figure S5).
None of the PDGFRa+/+ or PDGFRa+/J cohort mice (n=35 and
33, respectively) developed sarcomas by 76 weeks of age.
The above-described data suggest that increased PDGFRa
activation could be sufficient for sarcoma formation in the
absence of other experimental gene alterations. Oncogenes
often cooperate with additional mutations that disrupt tumor
suppressor pathways, such as INK4a/ARF, which is frequently
inactivated in malignant and recurrent forms of GIST (Sabah
et al., 2004). To examine the role of the tumor suppression
response in mutant PDGFRa signaling, we generated additional
cohorts of Ink4a/Arf and PDGFRa compound mutants.
PDGFRa+/+;Ink4a/Arf/ mice had an average tumor-free
survival span of >20 weeks (Figure 7A), consistent with previous
studies with Ink4a/Arf/ mice (Serrano et al., 1996). Loss of
Ink4a/Arf synergized with increased PDGFRa activation, such
that all Tam-treated PDGFRa+/K;Ink4a-Arf/mice (n=40) devel-
oped PDGFRa-expressing sarcomas of the skin or muscle308 Developmental Cell 16, 303–313, February 17, 2009 ª2009 Elseconnective tissue after a latency period of 10–19 weeks (Figures
7A and 7B). These sarcomas histologically resembled those
described earlier in PDGFRa+/K mice (Figures 7C–7E;
Figure S5). Two PDGFRa+/K;Ink4a/Arf/ mice also developed
tumorsof the large intestine thatmost resembledundifferentiated
fibrosarcomas and did not express TMEM16A (Figure S6),
a marker for GIST (West et al., 2004). In addition to sarcomas,
all PDGFRa+/K;Ink4a/Arf/mice developed accelerated fibrosis
of the skin and muscle at 10–19 weeks post-Tam that was
not evident in similarly aged PDGFRa+/K or Ink4a/Arf/ mice
(Figures 7F–7I). Gastrointestinal fibrosis was also often seen
in PDGFRa+/K;Ink4a/Arf/ mice that survived >15 weeks
(data not shown). Taken together, these data show that loss of
Ink4a/Arf cooperateswith increasedPDGFRa activity in sarcoma
formation and furthermore accelerates PDGFRa-driven fibrosis,
suggesting a previously unappreciated role for Ink4a/Arf in
limiting fibrotic diseases.
DISCUSSION
In this study, we explored the role of mouse PDGFRa by target-
ing mutant cDNAs with higher intrinsic kinase activity to the
PDGFRa locus; the effects of increased PDGFRa activation arevier Inc.
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Polyp Formation in Adult Mutants
(A) Schematic of gastrointestinal mucosa and
submucosa. Epithelial surface of villi, pink; circular
and longitudinal smooth muscle layers, red;
connective tissue, blue.
(B) Staining for b-galactosidase activity (blue) in
a ROSA26CreER/RLacZ intestine. Activity is seen in
individual cells of the submucosa and villus
mesenchyme (arrows) and in clones of epithelial
cells (asterisk).
(C) Kaplan-Meier survival plot of PDGFRa+/+;
ROSA26+/CreER (Wt, n=35), PDGFRa+/J;
ROSA26+/CreER (aJ, n=33), and PDGFRa+/K;
ROSA26+/CreER (aK, n=29) mice, beginning at the
time of Tam treatment. Gastrointestinal dysfunc-
tion in PDGFRa+/K mice results in significantly
diminished survival.
(D–F) Swiss roll preparations of small intestine
from Tam-treated cohort mice at 6–8 months after
treatment. Submucosal thickening is seen in
PDGFRa+/J and PDGFRa+/K embryos, stained
with hematoxylin and eosin.
(G–I)Wild-type,PDGFRa+/J, andPDGFRa+/K small
intestine stained with Masson’s trichrome (MT) to
visualize increasing collagen (blue) in mutant
tissue and fibrotic invasion of the circular smooth
muscle layer (asterisk in [I]). For purposes of orien-
tation, brackets indicate mucosa (M) and submu-
cosa (S).
(J) Two fibrous polyps from a PDGFRa+/K small
intestine, stained with MT. Collagen-rich polyp
cores (blue) are surfaced with intact mucosa.
(K) In situ hybridization for PDGFRa showing
expression (blue) in many cells of the fibrous
lesion.
(L) In situ hybridization for Kit, which is largely
absent within the lesion but is found in crypts.
(M) Immunohistochemistry for a-SMA (brown),
which is only expressed in nearby smooth muscle
layers and residual muscularis mucosa.
(N) Q-PCR shows increased expression of
PDGFRa, but not Kit in fibrotic PDGFRa+/K intes-
tine (mean ± standard deviation).thereby limited to cells that normally express the receptor. To
mimic separately the consequence of germline or somatic muta-
tion, we activated cDNA expression early in embryogenesis with
Meox2-Cre, or in a mosaic fashion in older mice by using a Tam-
inducible method. From the results of these experiments, we
conclude that a major biological outcome of increased PDGFRa
signaling is the activation of cellular programs that generate
connective tissue in both the embryo and adult.
The ureters and digestive tract are radially patterned tubes
composed of concentric layers of connective tissue and smooth
muscle surrounding a specialized epithelium and a lumenal
space. Cells lining the lumen express hedgehog signals from
E11.5 onward to regulate mesenchymal proliferation and
patterning (Ramalho-Santos et al., 2000; Yu et al., 2002). We
found thatPDGFRa and its principal ligandswere also expressed
during this time in a pattern that could affect epithelial-mesen-
chymal signaling during development of these organs. Increased
PDGFRa signaling affected stromal fibroblasts, which became
hyperplastic and generated fibrotic overgrowths. The smooth
muscle lineage was not directly affected, but we identified situa-Developtions in which smooth muscle structure was disrupted by
connective tissue overgrowth. Because PDGF ligands were
expressed in the prospective urothelium and mutant fibroblasts
were more responsive in a chemotaxis assay, PDGF signaling
might regulate the initial migration of metanephric or other
mesenchyme toward the distal ureteric bud. Fibroblasts isolated
from mutant embryos exhibited both constitutive and inducible
PDGFRa signaling, which is also consistent with enhanced
chemotaxis toward a source of ligand in vivo. Finally, mesen-
chymal progenitors in theureter andesophagusweremoreprolif-
erative when they expressedmutant PDGFRa. We conclude that
increased proliferation and enhancedmigration likely account for
the stromal hyperplasia seen in the developmental setting.
Two different PDGFRa-activating point mutations were tested
in this study, and we hypothesized that different biological
outcomes could result from these mutations because analogous
mutations in the closely related KIT receptor predict different
spectrums of neoplasia in humans: juxtamembrane domain
mutations produce GISTs, whereas kinase domain mutations
are commonly found in lymphomas, leukemias, and testicularmental Cell 16, 303–313, February 17, 2009 ª2009 Elsevier Inc. 309
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PDGFRa+/J and PDGFRa+/K Mice
All tissues were isolated from wild-type (Wt),
PDGFRa+/J (aJ), and PDGFRa+/K (aK) cohort
mice at 6–8 months after Tam treatment.
(A–C) Full thickness skin sections from Tam-
treated cohort mice were stained with Masson’s
trichrome (MT) to reveal collagen (blue). (A) Major
layers in wild-type skin are (top to bottom)
epidermis (e), dermis (d), adipose (a, bracket),
and muscle (m). (B and C) Both mutants have
increased collagen deposition associated with
every layer (asterisks) except epidermis.
(D and E) Sections of heart muscle stained with
MT. Collagen (blue) associates with vessels in (D)
wild-type but infiltrates broadly in (E) PDGFRa+/K
heart muscle (arrows).
(F and G) Lung tissue stained with MT. (F) Wild-
type has little collagen (blue), but fibrosis is seen
in (G) PDGFRa+/J as deposits around the bronchi-
oles (asterisk).
(H and I) Skeletal muscle of the abdomen stained
with MT. Collagen (blue) associates only with muscle fascia in (H) wild-type, but invades deep into (I) mutant muscle (asterisks).
(J) In situ hybridization for PDGFRa expression in fibrotic PDGFRa+/K skeletal muscle. Positive cells (blue) are found within the fibrotic lesion (asterisk).
(K) Quantification of fibrosis based on tissue sections stained with picosirius red (mean of three animals per genotype ± standard deviation).
(L) IHC detection of phospho-PLCg1 (brown) is sparse in wild-type muscle fascia (left panel, red arrows) compared to abundant phospho-PLCg1 (brown) in
fibrotic PDGFRa+/K muscle fascia (center panel). Right panel shows in situ hybridization for PDGFRa expression in an adjacent section of PDGFRa+/K muscle.tumors (Corless et al., 2004). A biological difference between the
two PDGFRa mutations was clearly revealed in our models by
the increased severity of mesenchymal defects and fibrosis in
PDGFRa+/K mice as compared to PDGFRa+/J mice. Unlike
human KIT mutations, however, our PDGFRa mutations gener-
ated a similar spectrum of phenotypes with differing severity.
Also, the increased severity of aK-driven phenotypes is concor-
dant with the observed bias toward PDGFRa D842V in human
tumors. Whereas neither of the PDGFRa mutations we tested
has been reported as a germline mutation in human families,
the V561D mutation was identified in a single individual exhibit-
ing GISTs plus multiple recurrent fibroid polyps (Pasini et al.,
2007), similar to the polyps that we observed in this study.310 Developmental Cell 16, 303–313, February 17, 2009 ª2009 ElseA few sarcomas appeared in our mutant mice with increased
PDGFRa activation, but only after long latency, implying that
other gene alterations might cooperate in tumorigenesis. One of
the most frequently mutated loci in human cancers is INK4a/
ARF (Ruas and Peters, 1998), and previous studies in mice have
shown a synergistic effect on neoplasia when oncogenic RTK
signaling is combined with loss of Ink4a/Arf (Sharp et al., 2002).
More specifically, loss of Ink4a/Arf has been shown to facilitate
glioblastoma progression in a mouse model based on PDGF-
PDGFR autostimulation (Dai et al., 2001; Hesselager et al.,
2003).Whenwe inducedPDGFRamutations in an Ink4a/Arf-defi-
cient background to investigate the cooperative effects in tumor-
igenesis, sarcoma formation was accelerated. Furthermore,Figure 7. Loss of Ink4a/Arf Accelerates
PDGFRa-DrivenTumorigenesisandFibrosis
(A) Kaplan-Meier survival plot of PDGFRa+/K;
Ink4aArf/;ROSA26+/CreER mice (n=40) versus
Ink4aArf/;ROSA26+/CreER littermates (n=21).
Mice were treated with Tam at E18.0, and the
plot begins 1 day later (at birth). All PDGFRa+/K;
Ink4aArf/ mutants developed sarcomas and
fibrosis before 19 weeks with a mean tumor inci-
dence at 14 weeks.
(B) Ventral view of tumors on two PDGFRa+/K;
Ink4aArf/;ROSA26+/CreER mice at the time of
necropsy, 14 weeks after Tam treatment.
(C) Representative sarcoma of the skin with strong
expression of PDGFRa shown by in situ hybridiza-
tion (blue). Intact epidermis covers the upper
surface of the tumor. hf, hair follicle.
(D) The same tumor as (C) stained withMasson’s trichrome (MT) to show collagen (blue) in the normal dermis, but not in the undifferentiated tumor cells (red).White
spaces are enveloped adipocytes.
(E) High-power image of a representative sarcoma stained with hematoxylin and eosin. Nuclei are highly pleiomorphic with numerous mitotic figures.
(F–I) Skin and abdominal muscle from cohort mice at 13 weeks after Tam,treatment: tissues were stained with MT to reveal collagen (blue). Loss of Ink4a/Arf syn-
ergizes with the aKmutation to dramatically accelerate the fibrosis of skin andmuscle in double mutants (asterisks in [I]). Other genotypes have normal-appearing
connective tissue at this time.vier Inc.
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nancy in PDGFRa+/K or PDGFRa+/J mice with wild-type Ink4a/
Arf, but two gastrointestinal tumors arose in young PDGFRa+/K;
Ink4a/Arf/ mice. These tumors appeared to be Kit negative
and most resembled poorly differentiated fibrosarcomas,
although there is a paucity of specific markers for GISTs that do
not express Kit. Because GISTs are generally diagnosed in older
patients, it remains possible that PDGFRa-driven GISTs would
eventually appear in the mice if fibrosis and other sarcomas did
not shorten the animal’s life span.
Increased PDGFRa signaling in both the embryo and in the
adult led toconnective tissuehyperplasiaand increasedextracel-
lular matrix deposition. In the adult, this resulted in fibrosis with
a striking phenotypic overlap with the human autoimmune
disease systemic sclerosis. Skin tightening was observed with
age due to excessive connective tissue deposition, and, further-
more, the skeletal muscle, heart, lung, kidney, and intestine
became scarred with infiltrates of matrix-producing fibroblasts.
Interestingly, we noted that experimental loss of Ink4a/Arf
dramatically accelerated thedevelopmentof fibrotic lesions, sug-
gesting that cells are able to limit the effects of PDGFRa signaling
through an Ink4a/Arf-dependent pathway. This property may
relate to previously known tumor suppression roles of Ink4a/Arf,
which is known to respond to stress pathways and hyperprolifer-
ative signals by enhancing the growth-suppressing activities of
p53 and p16/Rb. It is clear that cell senescence plays an impor-
tant role in suppressing tumor growth in vivo; however, it was
recently shown that acute fibrosis in chemically treated murine
livers can be limited by a senescence response (Krizhanovsky
et al., 2008). Therefore, PDGFRa hyperproliferative signaling
could lead to Ink4a/Arf-dependent senescenceof activatedfibro-
blasts, thereby suppressing both tumorigenesis and fibrosis.
Previous investigations have suggested a role for PDGF
signaling in the fibrosis of individual organs, including the heart
(Ponten et al., 2005), liver (Campbell et al., 2005), skin (Distler
et al., 2007), and lung (Abdollahi et al., 2005). Altered TGFb1
signaling has also been implicated in many fibrotic conditions,
and consistent with the model that PDGF acts independently or
downstream of TGFb1, we did not detect changes in Smad2/3
phosphorylation in unstimulated mutant fibroblasts (data not
shown). Our work provides in vivo evidence that increased
PDGFRa signaling can be sufficient to drive systemic connective
tissue disease in the mouse tissues and organ systems that are
relevant to human systemic sclerosis. Because systemic autoan-
tibody stimulation of PDGFRs has recently been hypothesized to
influence systemic sclerosis (Baroni et al., 2006), it could be infor-
mative to use this type of an approach to determine if increased
PDGFRb signaling can contribute to fibrosis in other organs or
produce the vascular restriction phenotypes also seen in this
disease. This work also establishes an excellent animal model
for testing novel therapeutic approaches for blocking aberrant
PDGFRa signaling in human systemic sclerosis.
EXPERIMENTAL PROCEDURES
Mice
A detailed description of ES cell targeting and vector design is provided in
Supplemental Experimental Procedures. Protocols for the derivation of mutant
mice were approved by our IACUC committee. Embryos and pups generatedDevelopmwith Meox2-Cre were examined in both a mixed B6/129 and pure 129 back-
grounds, with identical phenotypes. ROSA26-CreER mice were obtained
from the Jackson Laboratories, and Ink4/aArf/ mice were obtained from
the NCI mouse repository.
To generate mouse cohorts for survival studies, PDGFRa+/(s)J or PDGFRa+/(s)K
heterozygotes were crossed with ROSA26CreER/CreER homozygotes. Tamoxifen
(Tam) (Sigma)dissolved incornoil (20mg/ml)was administeredby intraperitoneal
injection under one of two schedules: (1) pregnant females were treated with
60 mg/kg Tam at embryonic day 18.0 to generate cohort offspring, or (2) cohort
offspring were treated with 200 mg/kg Tam at postnatal day 30. Recombination
efficiency in test animals was determined as described in Supplemental Data.
Both schedules gave the same phenotypes after similar latency; therefore, mice
from both groups are presented together (in Kaplan-Meier survival plots, etc.).
To visualize Tam-induced Cre recombination in tissues by activation of the
ROSA26RlacZ reporter (Soriano, 1999), ROSA26CreER/RlacZ mice were treated
with both treatment schedules described above, then sacrificed after 5 days.
Nearly all tissues exhibited mosaic recombination, except the brain.
Togeneratecohortsona tumor-susceptiblebackground,PDGFRa+/(S)K;Ink4a/
Arf+/ transheterozygotes were crossed to ROSA26CreER/CreER;Ink4aArf/
double homozygotes, and Tam was administered on schedule 1 described
above.All cohortmicegeneratedwithROSA26-CreERwereexamined inamixed
B6/129 background.
Cells
To generate mouse embryonic fibroblasts (MEFS), individual E13.5 embryos
were isolated from crosses between PDGFRa+/(S)J or PDGFRa+/(S)K heterozy-
gotes and Meox2+/Cre heterozygotes. Alternatively, Meox2+/Cre;PDGFRa+/
double heterozygotes were used in these crosses to produce PDGFRa/K
MEFs. Additional experimental details are described in Supplemental Data.
Immunoprecipitation and Western Blots
Cleared lysate was quantified for protein concentration (DC Protein Assay,
Bio-Rad), normalized across samples, and then immunoprecipitated with
a rabbit anti-PDGFRa antibody 27P (a kind gift from Dr. Andrius Kazlauskas)
and purified with Protein-A agarose (Sigma). Immunoprecipitates were sepa-
rated on 7.5%SDS-PAGE gels and blotted onmembranes with anti-phospho-
tyrosine antibody 4G10 (Upstate). After stripping, membranes were reprobed
for total PDGFRa. For signaling proteins, cleared and normalized lysates were
separated on 12% SDS-PAGE gels and blotted on membranes with rabbit
antibodies against phosphoAKT (Ser473), phosphoErk1/2 (Thr202/Tyr204),
and phosphoPLCg1 (and unphosphorylated proteins) according to manufac-
turer’s instructions (Cell Signaling).
Tissues and Histology
Embryos and adult tissue were fixed with either 10% buffered formalin (Fisher)
or Bouin’s solution (Sigma), paraffin embedded, and sectioned at 8mm before
staining. Fibrosis in various organs was quantified in three mice per genotype
by staining with picosirius red, followed by photography and image analysis to
measure the percentage of collagen per tissue area (ImageJ). For immunohis-
tochemistry, a-SMA antibody (1A4, Sigma) or phospho-PLCg1 antibody
(Cell Signaling) was used with avidin-biotin amplification and DAB staining
(ABC kit, Vector labs). For bromodeoxyuridine (BrdU) labeling, we injected
50mg Brdu/kg for a 90min pulse. Proliferating cells (BrdU+) were detected
with aBrdU antibody at 1:20 dilution (Sigma). Hematoxylin was used as a coun-
terstain for immunohistochemistry. For in situ hybridizations, formalin-fixed
tissues were cryoprotected in 20% sucrose solution and cryosectioned at
a 14 mm thickness. Dig-labeled RNA probes were synthesized with DIG RNA
labeling mix (Roche) from cDNA templates (see Table S3 for probe informa-
tion). Hybridized probes were detected with AP-conjugated anti-Dig Fab frag-
ments (Roche) and developed with NBT/BCIP (Roche). b-galactosidase
activity from ROSA26R-lacZ tissue was assayed as previously described (Sor-
iano, 1999) with development at 37C overnight. Eosin or nuclear fast red were
used as a counterstain for in situ hybridizations and b-gal assays.
SUPPLEMENTAL DATA
Supplemental Data include Experimental Procedures, eight figures, and three
tables and can be found with this article online at http://www.cell.com/
developmental-cell/supplemental/S1534-5807(08)00513-3.ental Cell 16, 303–313, February 17, 2009 ª2009 Elsevier Inc. 311
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